A Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 2a Study With an Extension Phase to Evaluate the Efficacy and Safety of BAY 3401016 in Participants Aged 18 to 45 With Alport Syndrome
Latest Information Update: 02 Nov 2026
At a glance
- Drugs BAY 3401016 (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Acronyms ASSESS
- Sponsors Bayer
Most Recent Events
- 18 Sep 2026 Status changed from recruiting to active, no longer recruiting.
- 20 Aug 2026 Planned End Date changed from 27 Jul 2028 to 29 Nov 2027.
- 20 Aug 2026 Planned primary completion date changed from 27 Jul 2028 to 29 Nov 2027.